Company intelligence / Profile preview
Sling Therapeutics, Inc.
Ann Arbor, Michigan, United Statesslingtx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Positive topline results from Phase 2b/3 LIDS clinical trial of linsitinib announced in January 2025. The trial met its primary endpoint of proptosis reduction with statistical significance at 150mg BID dose. Linsitinib was well-tolerated with no drug-related hearing impairments or significant hyperglycemia. A confirmatory Phase 3 trial is on track to commence in 2025.
- Therapeutic areas
- EndocrinologyRare Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sling Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sling Therapeutics, Inc..